Keywords: Merck KGaA Theratechnologies, Egrifta, Lipodystrophy, HIV, Bionovo, Menerba, Hot flashes, USA, FDA

US FDA approves Merck KGaA Egrifta to treat lipodystrophy in HIV patients and development plan for Bionovo’s Menerba

Article | 11 November 2010

Print This

The US Food and Drug Administration yesterday approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a condition in which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in